Evidence map›Paper›PMID 35233240›Full record

ArticleJournal of contemporary brachytherapy2022

Effect of a lead block on alveolar bone protection in image-guided high-dose-rate interstitial brachytherapy for tongue cancer: using model-based dose calculation algorithms to correct for inhomogeneity.

Hironori Akiyama, Ken Yoshida, Tadashi Takenaka, Tadayuki Kotsuma, Koji Masui, Hajime Monzen, Iori Sumida, Yutaka Tsujimoto, Mamoru Miyao, Hiroki Okumura and 11 more

Open access · goldAbstract read
In one paragraph

Article in Journal of contemporary brachytherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 3 countries.

Hironori AkiyamaDepartment of Oral Radiology, Osaka Dental University, Osaka, Japan.
Ken YoshidaDepartment of Radiology, Kansai Medical University Medical Center, Osaka, Japan.
Tadashi TakenakaDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tadayuki KotsumaDepartment of Radiation Oncology, Osaka Rosai Hospital, Osaka, Japan.
Koji MasuiDepartment of Radiology, Fukuchiyama City Hospital, Kyoto, Japan.
Hajime MonzenDepartment of Medical Physics, Graduate School of Medical Sciences, Kindai University, Osaka, Japan.
Iori SumidaDepartment of Radiation Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yutaka TsujimotoDepartment of Radiation Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Mamoru MiyaoDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Hiroki OkumuraDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Taiju ShimboDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Hideki TakegawaDepartment of Radiology, Kansai Medical University, Osaka, Japan.
Naoya MurakamiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Koji InabaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tairo KashiharaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Zoltán Takácsi-NagyCenter of Radiotherapy, National Institute of Oncology, Department of Oncology, Semmelweis University, Budapest, Hungary.
Nikolaos TselisDepartment of Radiotherapy and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
Hideya YamazakiDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Eiichi TanakaDepartment of Radiation Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Keiji NiheiDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Yoshiko ArijiDepartment of Oral Radiology, Osaka Dental University, Osaka, Japan.
Osaka University of Pharmaceutical Sciences · JPTokyo National Hospital · JPKansai Medical University · JPKyoto Prefectural University of Medicine · JPOsaka Dental University · JPOsaka National Hospital · JPFukuyama City Hospital · JPKindai University · JPNational Institute of Oncology · HUOsaka Rosai Hospital · JPOsaka University · JPUniversity Hospital Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to evaluate the effect of a lead block for alveolar bone protection in image-guided high-dose-rate interstitial brachytherapy for tongue cancer. MATERIAL AND

methodsWe treated 6 patients and delivered 5,400 cGy in 9 fractions using a lead block. Effects of lead block (median thickness, 4 mm) on dose attenuation by distance were visually examined using TG-43 formalism-based dose distribution curves to determine whether or not the area with the highest dose is located in the alveolar bone, where there is a high-risk of infection. Dose re-calculations were performed using TG-186 formalism with advanced collapsed cone engine (ACE) for inhomogeneity correction set to cortical bone density for the whole mandible and alveolar bone, water density for clinical target volume (CTV), air density for outside body and lead density, and silastic density for lead block and its' silicon replica, respectively.

resultsThe highest dose was detected outside the alveolar bone in five of the six cases. For dose-volume histogram analysis, median minimum doses delivered per fraction to the 0.1 cm

conclusionsThe results suggested that using a lead block for alveolar bone protection with a thickness of about 4 mm, can shift the highest dose area to non-alveolar regions. In addition, it reduced D0.1cm

Indexed as

bone protectionbrachytherapyinhomogeneity correctionlead blocktongue cancer

Identifiers

PMID35233240
PMCPMC8867239
OpenAlexW4211190697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.